Literature DB >> 1581215

A patient with von Willebrand's disease characterized by a compound heterozygosity for a substitution of Arg854 by Gln in the putative factor-VIII-binding domain of von Willebrand factor (vWF) on one allele and very low levels of mRNA from the second vWF allele.

K Peerlinck1, J C Eikenboom, H K Ploos Van Amstel, W Sangtawesin, J Arnout, P H Reitsma, J Vermylen, E Briët.   

Abstract

We describe a patient with a lifelong bleeding disorder previously classified as von Willebrand's disease (vWD) type I. The factor VIII (FVIII) level in this patient was disproportionately low and we showed that this was due to a decreased factor VIII binding capacity of her vWF. To characterize the molecular defect in this type of vWD, a cDNA-dependent polymerase chain reaction (PCR) amplification was performed using platelet RNA as a template. Direct sequencing of the amplified fragment, which encodes for the FVIII-binding domain, showed a single nucleotide change in exon 20 at codon 854, resulting in the substitution of CAG glutamine (Gln) for CGG arginine (Arg). At the level of the cDNA only the mutated sequence was found, whereas at genomic DNA level the patient was heterozygous for this mutation. This patient is therefore a compound heterozygote for a point mutation resulting in a FVIII-binding defect and a vWF allele with low transcript levels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1581215     DOI: 10.1111/j.1365-2141.1992.tb08145.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  A novel case of compound heterozygosity with "Normandy"/type I von Willebrand disease (vWD). Direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type I vWD.

Authors:  V Siguret; J M Lavergne; G Chérel; C Boyer-Neumann; A S Ribba; B R Bahnak; D Meyer; G Piétu
Journal:  Hum Genet       Date:  1994-02       Impact factor: 4.132

Review 2.  Autosomal recessive transmission of hemophilia A due to a von Willebrand factor mutation.

Authors:  R J Wise; B M Ewenstein; J Gorlin; S C Narins; M Jesson; R I Handin
Journal:  Hum Genet       Date:  1993-05       Impact factor: 4.132

3.  Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF.

Authors:  Jennifer E Huffman; Paul S de Vries; Alanna C Morrison; Maria Sabater-Lleal; Tim Kacprowski; Paul L Auer; Jennifer A Brody; Daniel I Chasman; Ming-Huei Chen; Xiuqing Guo; Li-An Lin; Riccardo E Marioni; Martina Müller-Nurasyid; Lisa R Yanek; Nathan Pankratz; Megan L Grove; Moniek P M de Maat; Mary Cushman; Kerri L Wiggins; Lihong Qi; Bengt Sennblad; Sarah E Harris; Ozren Polasek; Helene Riess; Fernando Rivadeneira; Lynda M Rose; Anuj Goel; Kent D Taylor; Alexander Teumer; André G Uitterlinden; Dhananjay Vaidya; Jie Yao; Weihong Tang; Daniel Levy; Melanie Waldenberger; Diane M Becker; Aaron R Folsom; Franco Giulianini; Andreas Greinacher; Albert Hofman; Chiang-Ching Huang; Charles Kooperberg; Angela Silveira; John M Starr; Konstantin Strauch; Rona J Strawbridge; Alan F Wright; Barbara McKnight; Oscar H Franco; Neil Zakai; Rasika A Mathias; Bruce M Psaty; Paul M Ridker; Geoffrey H Tofler; Uwe Völker; Hugh Watkins; Myriam Fornage; Anders Hamsten; Ian J Deary; Eric Boerwinkle; Wolfgang Koenig; Jerome I Rotter; Caroline Hayward; Abbas Dehghan; Alex P Reiner; Christopher J O'Donnell; Nicholas L Smith
Journal:  Blood       Date:  2015-06-23       Impact factor: 22.113

4.  Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains.

Authors:  Monica Sacco; Stefano Lancellotti; Mattia Ferrarese; Francesco Bernardi; Mirko Pinotti; Maira Tardugno; Erica De Candia; Leonardo Di Gennaro; Maria Basso; Betti Giusti; Massimiliano Papi; Giordano Perini; Giancarlo Castaman; Raimondo De Cristofaro
Journal:  Blood Adv       Date:  2020-07-28

5.  Identification and functional analysis of a novel von Willebrand factor mutation in a family with type 2A von Willebrand disease.

Authors:  Jing Dong; Xiaojuan Zhao; Sensen Shi; Zhenni Ma; Meng Liu; Qingyu Wu; Changgeng Ruan; Ningzheng Dong
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.